On March 29, 2020, AbCellera Biologics, Inc., a biopharmaceutical company based in New York City, announced that it has entered into a multi-year agreement to acquire a second antibody, Bamlanivimab, for the treatment of COVID-19. The deal is subject to approval by the U.S. Department of Health and Human Services. The deal is subject to approval by the Department of Health and Human Services.  The deal is subject to regulatory approval.  According to the company's press release, the deal is subject to approval by the Department of Commerce and the Department of Health and Human Services.  In a parallel action, the U.S. Attorney's Office for the District of New York today announced criminal charges against AbCellera.  The SEC's complaint, filed in federal court in Manhattan, charges AbCellera with violations of the antifraud provisions of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Sections 206(1) and 206(2) of the Investment Advisers Act of 1940.  The SEC's complaint charges AbCellera with violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, AbCellera has consented to the entry of a final judgment that permanently enjoins it from violating Section 10(b) of the Exchange Act.  The settlement is subject to court approval.  The SEC appreciates the assistance of the U.S. Attorney’s Office for the District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC encourages investors to check the background of anyone selling or offering them an investment using the SEC’s investor.gov website.  The SEC encourages investors to check the backgrounds of people selling or offering them an investment using the free and simple search tool on Investor.gov.